{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T10:24:22Z","timestamp":1770978262224,"version":"3.50.1"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs Aging"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1007\/s40266-017-0458-6","type":"journal-article","created":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T02:45:34Z","timestamp":1491014734000},"page":"393-400","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Aflibercept: A Review in Macular Oedema Secondary to Branch Retinal Vein Occlusion"],"prefix":"10.1007","volume":"34","author":[{"given":"Sheridan M.","family":"Hoy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,4,1]]},"reference":[{"key":"458_CR1","unstructured":"American Academy of Ophthalmology. Retinal vein occlusions: preferred practice pattern. 2015. \n                        http:\/\/www.aao.org\/\n                        \n                    . Accessed 14 Feb 2017."},{"key":"458_CR2","unstructured":"The Royal College of Ophthalmologists. Retinal vein occlusion (RVO) guidelines. 2015. \n                        http:\/\/www.rcophth.ac.uk\/\n                        \n                    . Accessed 14 Feb 2017."},{"issue":"1","key":"458_CR3","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.mayocp.2011.10.001","volume":"87","author":"MW Stewart","year":"2012","unstructured":"Stewart MW. The expanding role of vascular endothelial growth factor inhibitors in ophthalmology. Mayo Clin Proc. 2012;87(1):77\u201388.","journal-title":"Mayo Clin Proc"},{"key":"458_CR4","unstructured":"Bayer Pharma AG. Eylea 40\u00a0mg\/ml solution for injection in pre-filled syringe: EU summary of product characteristics. 2016. \n                        http:\/\/www.ema.europa.eu\/ema\/\n                        \n                    . Accessed 14 Feb 2017."},{"key":"458_CR5","unstructured":"Regeneron Pharmaceuticals Inc. EYLEA\u00ae (aflibercept) injection for intravitreal injection: US prescribing information. 2016. \n                        http:\/\/www.fda.gov\/\n                        \n                    . Accessed 14 Feb 2017."},{"issue":"10","key":"458_CR6","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1007\/s40265-015-0421-y","volume":"75","author":"GM Keating","year":"2015","unstructured":"Keating GM. Aflibercept: a review of its use in diabetic macular oedema. Drugs. 2015;75(10):1153\u201360.","journal-title":"Drugs."},{"issue":"5","key":"458_CR7","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1007\/s40266-014-0176-2","volume":"31","author":"LPH Yang","year":"2014","unstructured":"Yang LPH, McKeage K. Intravitreal aflibercept (Eylea\u00ae): a review of its use in patients with macular oedema secondary to central retinal vein occlusion. Drugs Aging. 2014;31(5):395\u2013404.","journal-title":"Drugs Aging"},{"issue":"10","key":"458_CR8","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1007\/s40266-012-0015-2","volume":"29","author":"JE Frampton","year":"2012","unstructured":"Frampton JE. Aflibercept for intravitreal injection: in neovascular age-related macular degeneration. Drugs Aging. 2012;29(10):839\u201346.","journal-title":"Drugs Aging"},{"issue":"17","key":"458_CR9","doi-asserted-by":"publisher","first-page":"11393","DOI":"10.1073\/pnas.172398299","volume":"99","author":"J Holash","year":"2002","unstructured":"Holash J, Davis S, Papadopoulos N, et al. VEGF-trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci USA. 2002;99(17):11393\u20138.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"2","key":"458_CR10","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/s10456-011-9249-6","volume":"15","author":"N Papadopoulos","year":"2012","unstructured":"Papadopoulos N, Martin J, Ruan Q, et al. Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis. 2012;15(2):171\u201385.","journal-title":"Angiogenesis"},{"issue":"11","key":"458_CR11","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.4155\/cli.13.94","volume":"3","author":"MW Stewart","year":"2013","unstructured":"Stewart MW. Aflibercept ophthalmic solution: drug development and clinical uses. Clin Invest. 2013;3(11):1045\u201356.","journal-title":"Clin Invest."},{"issue":"2","key":"458_CR12","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1002\/jcp.10246","volume":"195","author":"Y Saishin","year":"2003","unstructured":"Saishin Y, Saishin Y, Takahashi K, et al. VEGF-TRAPR1R2 suppresses choroidal neovascularization and VEGF-induced breakdown of the blood-retinal barrier. J Cell Physiol. 2003;195(2):241\u20138.","journal-title":"J Cell Physiol"},{"issue":"5","key":"458_CR13","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1097\/IAE.0b013e31827b646d","volume":"33","author":"DA Ammar","year":"2013","unstructured":"Ammar DA, Mandava N, Kahook MY. The effects of aflibercept on the viability and metabolism of ocular cells in vitro. Retina. 2013;33(5):1056\u201361.","journal-title":"Retina."},{"issue":"7","key":"458_CR14","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1136\/bjophthalmol-2013-303130","volume":"97","author":"S Schnichels","year":"2013","unstructured":"Schnichels S, Hagemann U, Januschowski K, et al. Comparative toxicity and proliferation testing of aflibercept, bevacizumab and ranibizumab on different ocular cells. Br J Ophthalmol. 2013;97(7):917\u201323.","journal-title":"Br J Ophthalmol"},{"issue":"Suppl 1","key":"458_CR15","doi-asserted-by":"publisher","first-page":"i11","DOI":"10.1136\/bjophthalmol-2014-305302","volume":"98","author":"D Malik","year":"2014","unstructured":"Malik D, Tarek M, Caceres del Carpio J, et al. Safety profiles of anti-VEGF drugs: bevacizumab, ranibizumab, aflibercept and ziv-aflibercept on human retinal pigment epithelium cells in culture. Br J Ophthalmol. 2014;98(Suppl 1):i11\u20136.","journal-title":"Br J Ophthalmol"},{"issue":"12","key":"458_CR16","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.3109\/02713683.2012.727521","volume":"37","author":"JB Christoforidis","year":"2012","unstructured":"Christoforidis JB, Williams MM, Kothandaraman S, et al. Pharmacokinetic properties of intravitreal I-124-aflibercept in a rabbit model using PET\/CT. Curr Eye Res. 2012;37(12):1171\u20134.","journal-title":"Curr Eye Res"},{"issue":"1","key":"458_CR17","doi-asserted-by":"publisher","first-page":"5","DOI":"10.4081\/eye.2011.e5","volume":"1","author":"MW Stewart","year":"2011","unstructured":"Stewart MW. What are the half-lives of ranibizumab and aflibercept (VEGF Trap-eye) in human eyes? Calculations with a mathematical model. Eye Rep. 2011;1(1):5.","journal-title":"Eye Rep."},{"issue":"3","key":"458_CR18","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1016\/j.ophtha.2014.08.031","volume":"122","author":"PA Campochiaro","year":"2015","unstructured":"Campochiaro PA, Clark WL, Boyer DS, et al. Intravitreal aflibercept for macular edema following branch retinal vein occlusion: the 24-week results of the VIBRANT study. Ophthalmology. 2015;122(3):538\u201344.","journal-title":"Ophthalmology"},{"issue":"2","key":"458_CR19","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/j.ophtha.2015.09.035","volume":"123","author":"WL Clark","year":"2016","unstructured":"Clark WL, Boyer DS, Heier JS, et al. Intravitreal aflibercept for macular edema following branch retinal vein occlusion: 52-week results of the VIBRANT study. Ophthalmology. 2016;123(2):330\u20136.","journal-title":"Ophthalmology"},{"key":"458_CR20","unstructured":"European Medicines Agency. Eylea (aflibercept): assessment report. 2015. \n                        http:\/\/www.ema.europa.eu\/ema\/\n                        \n                    . Accessed 14 Feb 2017."},{"key":"458_CR21","unstructured":"Regeneron Pharmaceuticals Inc. EYLEA\u00ae (aflibercept) injection receives approval in Japan for the treatment of retinal vein occlusion. 2015. \n                        http:\/\/www.regeneron.com\/\n                        \n                    . Accessed 14 Feb 2017."},{"key":"458_CR22","unstructured":"National Institute for Health and Care Excellence. Aflibercept for treating visual impairment caused by macular oedema after branch retinal vein occlusion. 2016. \n                        http:\/\/www.nice.org.uk\/guidance\/TA409\n                        \n                    . Accessed 14 Feb 2017."},{"key":"458_CR23","unstructured":"Novartis Europharm Limited. Lucentis (ranibizumab) 10\u00a0mg\/ml solution for injection: EU summary of product characteristics. 2016. \n                        http:\/\/www.ema.europa.eu\/ema\/\n                        \n                    . Accessed 14 Feb 2017."},{"issue":"Suppl 1","key":"458_CR24","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1159\/000337152","volume":"227","author":"V Chong","year":"2012","unstructured":"Chong V. Biological, preclinical and clinical characteristics of inhibitors of vascular endothelial growth factors. Ophthalmologica. 2012;227(Suppl 1):2\u201310.","journal-title":"Ophthalmologica."},{"issue":"6","key":"458_CR25","doi-asserted-by":"publisher","first-page":"e007527","DOI":"10.1136\/bmjopen-2014-007527","volume":"5","author":"SA Regnier","year":"2015","unstructured":"Regnier SA, Larsen M, Bezlyak V, et al. Comparative efficacy and safety of approved treatments for macular oedema secondary to branch retinal vein occlusion: a network meta-analysis. BMJ Open. 2015;5(6):e007527.","journal-title":"BMJ Open"}],"container-title":["Drugs & Aging"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-017-0458-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40266-017-0458-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-017-0458-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,4,27]],"date-time":"2017-04-27T15:07:38Z","timestamp":1493305658000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40266-017-0458-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4,1]]},"references-count":25,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,5]]}},"alternative-id":["458"],"URL":"https:\/\/doi.org\/10.1007\/s40266-017-0458-6","relation":{},"ISSN":["1170-229X","1179-1969"],"issn-type":[{"value":"1170-229X","type":"print"},{"value":"1179-1969","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,4,1]]}}}